While our recent mouse studies [36, 38] provide a firm basis for ALTIBRAIN, and our longstanding work on EPO treatment of cognitive impairment across animals and humans lends significant support, the translation of findings from animals to humans is often poor [11]. The gene discussed is EPO; the disease is Cognitive impairment.